Zhihong H. Chi

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 127 publications

Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study.

Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study.

Journal: BMC medicine

Published: January 20, 2026

Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy.

Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy.

Journal: Experimental hematology & oncology

Published: October 13, 2025

A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma.

A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma.

Journal: Nature communications

Published: August 08, 2025

MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.

MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 31, 2025

Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.

Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.

Journal: Urologic oncology

Published: June 30, 2025

Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective Analysis.

Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective Analysis.

Journal: Cancer investigation

Published: May 23, 2025

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

Journal: Cancer management and research

Published: February 05, 2025

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.

Journal: Journal for immunotherapy of cancer

Published: January 19, 2025

Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian.

Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian.

Journal: Journal of genetics and genomics = Yi chuan xue bao

Published: December 17, 2024

A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.

A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.

Journal: World journal of urology

Published: November 10, 2024

Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study.

Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 14, 2024

Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy.

Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy.

Journal: Journal of extracellular vesicles

Published: September 12, 2024

Showing 1-12 of 127

Last Updated: 09/26/2026